Interim Efficacy Analysis, Follow-up Milestone Period

No definition available.

Name:	clbs_InterimEfficacyAnalysisFollowupMilestonePeriod
Namespace Prefix:	clbs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Interim Efficacy Analysis, Percentage Threshold

+ References

No definition available.

+ Details

Name:	clbs_InterimEfficacyAnalysisPercentageThreshold
Namespace Prefix:	clbs_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Cohorts

+ References

No definition available.

+ Details

Name:	clbs_NumberofCohorts
Namespace Prefix:	clbs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_GrantsReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.

+ References

+ Details

Name:	us-gaap_GrantsReceivableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=clbs_TheSanfordProjectTRexStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

The Business Immunomodulation (Treg Technology) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016 cohort	May 04, 2017 USD ($)	Feb. 23, 2017 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Interim Efficacy Analysis, Percentage Threshold	50.00%
Interim Efficacy Analysis, Follow-up Milestone Period	6 years
Grants Receivable			$ 12.2
Grants Receivable, Current		$ 5.7
The Sanford Project: T-Rex Study [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of Cohorts \| cohort	2